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Objectives: To assess the efficacy and tolerability of Chondroitin 
sulfate (CS), a SYSADOA, in patients with knee osteoarthritis 
(KOA). 
Methods: Multicenter, double-blind, placebo-controlled, parallel- 
group study. Patients over 50 years with KOA (ACR criteria) were 
randomized to receive either CS 500 mg or PLA bid for a 6-month 
treatment period followed by a 2-month placebo period to inves- 
tigate the carry over effect. Inclusion criteria were pain intensity 
in the target knee _> 40 mm on a 100-mm visual analog scale 
(VAS) after a 2- to 7-day washout of NSAI Ds, Lequesne Algofunc- 
tional Index (LFI) score >6 and <12 and a radiological Kellgren - 
Lawrence stages 2 or 3. Outcome measures were pain (VAS), LFI 
score (0-24), quality of life scale (SF-12), patients and physicians 
global assessment conducted at baseline, 1,3, and 6 months for 
the treatment period and at the end of the study for the placebo 
period. In addition, the treatment response was assessed using 
the Outcome Measures in Clinical Trials (OMERACT-OARSI) cri- 
teria. The safety and tolerability were assessed by recording any 
adverse event and discontinuation of treatment. The intent-to- 
treat population was compared on change from baseline using 
baseline adjusted ANCOVA models with last observation carried 
forward. 
Results: The study enrolled 311 patients (62% female; mean 
age: 60.5 yrs): 155 were randomized to receive CS and 156 PLA. 
There was no difference between groups at entry in terms of 
demographics and disease characteristics. Three hundred and 
seven of 311 patients were included in the intent-to-treat nalysis. 
Pain intensity was significantly reduced in the CS group (41.1 %/- 
26.2mm) compared with the PLA group (31.6%/-19.9mm) after 6 
months treatment (P = 0.029) and LFI decreased by 24.8% (-2.3) 
in the CS group compared to 16.7% (-1.7) in the PLA group (P = 
0.109). The rate of responders (OMERACT-OARSI) was 68% for 
CS and 56% for PLA group (P = 0.029). Improvement was higher 
reported in the CS than PLA group for both patients (p=0.085) 
and investigators assessment of global efficacy (p=0.044). The 
SF-12 physical component was significantly improved in the CS 
compared with the PLA group after 6 months treatment (P = 
0.021).The rescue medication (paracetamol) was similarly used 
by both groups, on average 27% (P = 0.962). One or more ad- 
verse events were reported by 49% of the SC group, compared 
with 48% of the PLA group. All trends observed across the treat- 
ment period were confirmed in the placebo period. 
Conclusion: In this population of patients, CS 500mg bid was 
more effective than placebo particularly on pain, response rate, 
investigators assessment of efficacy and health-related quality 
of life across a 6-month treatment period. This study also con- 
firms the very good tolerance of CS and show a carry-over ef- 
fect of 2 months duration. Additionally, this randomized, multicen- 
tre, double blind, placebo controlled study confirms the capacity 
of OMERACT-OARSI responder criteria to detect clinically differ- 
ences between treatment groups. 
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Aim: Clinical and observational studies have confirmed that the 
use of non-selective (ns) NSAIDs is associated with upper gas- 
trointestinal (GI) toxicity, the effects of which may be mitigated by 
the use of PPIs. This study was designed to examine the extent 
of and the factors associated with the concurrent usage of nsN- 
SAIDs and PPIs among chronic nsNSAID users in the UK. 
Methods: This retrospective cohort study used a sample from the 
UK Mediplus ® database. Patients were identified based on their 
first (index) prescription (IRx) for a nsNSAID from 07/01/2002 to 
12/31/2002. Eligible patients were 40 years or older, used a single 
nsNSAID at the IRx date, and had at least 60 days of NSAID sup- 
ply during the 1 year follow-up period after IRx (chronic users). 
Patients were followed until the earlier of 1 year or switching to a 
cycloxygenase (COX)-2 selective inhibitor. Outcomes of interest 
were: absolute number of days of nsNSAID and PPI supply, pro- 
portion of patients taking PPIs stratified by GI risk factors, annual 
PPI possession ratio (defined as total days of PPI supply divided 
by total days of nsNSAID supply), annual PPI/nsNSAID overlap 
ratio (total days of PPI supply that overlap with nsNSAID supply 
divided by total nsNSAID days of supply), and factors associated 
with the concurrent use of nsNSAIDs and PPIs, assuming that pa- 
tients take medications as prescribed. A 2-part model was used 
to estimate the probability of concurrent use (logistic regression) 
and the level of concurrent use (generalized linear model with a 
log link function). 
Results: The mean age of the identified 19,257 nsNSAID pa- 
tients was 61.41 years (4-12.10), 51% were female, and 10% 
used a PPI during the follow-up period. The odds of receiving 
a PPI was higher in patients at risk of a GI event, however only 
6%, 12%, and 28% of patients with 1, 2, and _>3 GI risk factors, 
respectively, received a PPI. Total days of nsNSAID supply dur- 
ing the 1 year period was 165.01 (4-123.75) in PPI users and 
163.21 (4-128.63) in non-users. Among PPI users, the posses- 
sion ratio was 1.16 (4-1.55) and the overlap ratio 0.48 (4-0.39). 
The likelihood of an overlapping nsNSAIDs and PPI prescription 
was significantly higher in patients _> 65 years (OR: 1.20), with 
a history (defined as past year) of gastroprotective agent (GPA) 
use (16.33), dyspepsia/abdominal pain (1.20), any hospitalization 
(1.52), or cardiovascular disease (1.39), and those with concur- 
rent use of corticosteroids (1.91) or aspirin (1.36). Among PPI 
users, the only factor that was significantly associated with the 
level of overlap ratio was history of GPA use. 
Conclusions: The results suggest that nsNSAID users at risk of 
GI events were more likely to get a PPI prescribed than nsNSAID 
patients without these risk factors. In addition, overlap with nsN- 
SAID therapy appeared to be higher in patients with a history of 
GPA use, assuming that patients take medications as prescribed. 
However, among PPI users only about 48% of the nsNSAID days 
were overlapped by concomitant PPI therapy. 
